Friday, August 7, 2026 - Week 32

 

CAMP4 - Gaining momentum

- Approval for trials in Australia & +$50M of cash from investors:https://investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-secures-australian-regulatory-clearance

- Profile on CNBC Cures: https://www.cnbc.com/2026/08/06/camp4-advances-rare-disease-treatment-for-syngap1-into-human-trials.html Where they mentioned approval in Argentina!

 

$CAMP closed at $4.53 yesterday. https://www.google.com/finance/beta/quote/CAMP:NASDAQ

 

MAKE SURE YOU ARE REGISTERED WITH CONNECT

https://curesyngap1.org/curesyngap1connect/

 

USA 🇺🇲: Use your ICD-10, F78.A1

 

CITIZEN

Sign up now! https://www.citizen.health/ai-advocate/syngap1

 

SOCIAL MATTERS

5,156 LinkedIn.  https://www.linkedin.com/company/curesyngap1

1.6k YouTube.  https://www.youtube.com/@CureSYNGAP1

11.1k Twitter https://twitter.com/cureSYNGAP1

43.7k Insta https://www.instagram.com/curesyngap1

 

Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10

Episode 213 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Syngap Research Fund, 501(c)(3). Innehållet i podden är skapat av Syngap Research Fund, 501(c)(3) och inte av, eller tillsammans med, Poddtoppen.